Fierce Biotech Features Talus Bio’s Latest Funding Round

“Seattle-based Talus Bioscience has raised $11.2 million in an early fundraising round, money that will go toward advancing the biotech’s portfolio of preclinical cancer programs and helping to build out the biotech’s drug discovery platform.

California VC Two Bear Capital led the charge for the “seed+” round, with participation from WRF Capital, NFX, YC Continuity Fund, Funders Club VC, and BoxOne Ventures.

Talus Bio is targeting a challenging transcription factor linked to prostate cancer, plus brachyury-driven cancers. Brachyury is a transcription factor that regulates tumor development in chordoma—a rare bone tumor that forms in the spine or base of the skull.”

– Gabrielle Masson, Associate Editor at Fierce Biotech

Read the full story on Talus Bio’s seed+ round at Fierce Biotech.

‍